Transition Therapeutics Inc. Announces Agreement Amendment
TORONTO, Nov. 30, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) announces an amendment to its agreement with Elan Corporation, plc (NYSE:ELN) ("Elan") for the development and commercialization of lead Alzheimer's disease drug candidate, ELND005.